Smith & Nephew plc (NYSE:SNN) Shares Purchased by Quantinno Capital Management LP

Quantinno Capital Management LP boosted its position in shares of Smith & Nephew plc (NYSE:SNN - Free Report) by 83.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 97,818 shares of the medical equipment provider's stock after buying an additional 44,592 shares during the period. Quantinno Capital Management LP's holdings in Smith & Nephew were worth $2,404,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Principal Securities Inc. increased its stake in Smith & Nephew by 87.6% during the 4th quarter. Principal Securities Inc. now owns 1,480 shares of the medical equipment provider's stock worth $36,000 after buying an additional 691 shares in the last quarter. R Squared Ltd purchased a new stake in Smith & Nephew during the 4th quarter worth approximately $41,000. National Bank of Canada FI increased its stake in Smith & Nephew by 36.5% during the 4th quarter. National Bank of Canada FI now owns 1,667 shares of the medical equipment provider's stock worth $41,000 after buying an additional 446 shares in the last quarter. Hara Capital LLC increased its stake in Smith & Nephew by 391.4% during the 4th quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider's stock worth $60,000 after buying an additional 1,957 shares in the last quarter. Finally, Blue Trust Inc. increased its stake in Smith & Nephew by 26.0% during the 4th quarter. Blue Trust Inc. now owns 5,871 shares of the medical equipment provider's stock worth $144,000 after buying an additional 1,213 shares in the last quarter. 25.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. Canaccord Genuity Group boosted their price objective on Smith & Nephew from $27.00 to $28.00 and gave the stock a "hold" rating in a research note on Thursday, May 1st. HSBC lowered Smith & Nephew from a "buy" rating to a "hold" rating in a research report on Friday, April 25th. UBS Group lowered Smith & Nephew from a "buy" rating to a "neutral" rating in a research report on Wednesday, March 12th. Hsbc Global Res lowered Smith & Nephew from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. Finally, Wall Street Zen upgraded Smith & Nephew from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, February 26th. Six analysts have rated the stock with a hold rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $28.00.

Smith & Nephew Trading Up 0.9%

SNN traded up $0.25 during trading hours on Friday, reaching $28.65. The company's stock had a trading volume of 948,581 shares, compared to its average volume of 800,456. Smith & Nephew plc has a fifty-two week low of $23.69 and a fifty-two week high of $31.72. The stock has a market cap of $12.55 billion, a PE ratio of 13.26, a P/E/G ratio of 1.26 and a beta of 0.68. The business's 50-day moving average is $27.44 and its 200-day moving average is $26.35. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.51 and a quick ratio of 1.11.

Smith & Nephew Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Wednesday, May 28th. Investors of record on Friday, March 28th will be issued a $0.447 dividend. The ex-dividend date of this dividend is Friday, March 28th. This is a boost from Smith & Nephew's previous semi-annual dividend of $0.29. This represents a yield of 2.5%. Smith & Nephew's dividend payout ratio is currently 41.20%.

Smith & Nephew Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.